European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS

Rapid diagnosis of preeclampsia at the point-of-care

Cel

MOMM Diagnostics conceives a new generation of in-vitro diagnostic tests for early diagnosis of preeclampsia. Preeclampsia remains to this day one of the leading causes for maternal mortality. Early diagnosis is therefore vital to minimize complications and prepare adequately for birth. The startup is developing a solution using microscale solid-state sensors for electrical detection of biomarkers in blood, which would allow the detection of multiple biomarkers, using a single-use cartridge and a hand-held reader for diagnosis of the condition directly where the patients are being taken care of. Technology originating from results of the FETOPEN project RECORD-IT (Project ID: 664786) has shown promising innovation potential. MOMM Diagnostics aims to verify this potential for commercialization by assessing its competitiveness for point of care applications. The technology promises an increased signal to noise ratio at a smaller form factor and lower cost compared to commercially available technologies. The FET Innovation Launchpad will help to consolidate the intellectual property rights and develop a demonstrator to approach investors.

Zaproszenie do składania wniosków

H2020-FETOPEN-2018-2020

Zobacz inne projekty w ramach tego zaproszenia

Szczegółowe działanie

H2020-FETOPEN-2018-2019-2020-03

Koordynator

MOMM DIAGNOSTICS GMBH
Wkład UE netto
€ 72 000,00
Adres
Hochbergerstrasse 60C
4057 Basel
Szwajcaria

Zobacz na mapie

MŚP

Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant.

Tak
Region
Schweiz/Suisse/Svizzera Nordwestschweiz Basel-Stadt
Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Linki
Koszt całkowity
€ 163 125,00

Uczestnicy (1)